Sinphar Pharmaceutical Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	864.14	1,076	1,074	1,238	1,195
Short-Term Investments	123.42	95.41	-	-	43.44
Trading Asset Securities	7.07	6.96	6.66	6.66	6.66
Cash & Short-Term Investments	994.63	1,178	1,081	1,244	1,245
Cash Growth	-15.57%	8.96%	-13.11%	-0.05%	4.24%
Accounts Receivable	713.86	641.9	643.47	685.19	592.97
Other Receivables	35.58	34.81	34.27	31.43	29.15
Receivables	749.44	676.71	677.73	716.62	622.12
Inventory	761.14	751.35	876.9	804.31	820.62
Prepaid Expenses	14.21	12.96	7.08	8.45	5.7
Other Current Assets	9.82	5.3	5.75	4.86	10.03
Total Current Assets	2,529	2,624	2,649	2,778	2,703
Property, Plant & Equipment	3,222	3,285	3,247	3,139	3,224
Long-Term Investments	52.68	54.64	22.21	24.7	20.36
Other Intangible Assets	59.52	72.16	71.82	86.98	117.3
Long-Term Deferred Tax Assets	195.49	185.37	170.86	52.11	74.88
Other Long-Term Assets	94.28	76.62	90.71	103.65	81.24
Total Assets	6,153	6,298	6,251	6,185	6,221
Accounts Payable	210.49	185.45	291.37	323.74	201.42
Short-Term Debt	188	370	400	447	587
Current Portion of Long-Term Debt	48.12	351.29	50.72	50.34	61.28
Current Portion of Leases	0.58	-	-	-	-
Current Income Taxes Payable	55.58	39.36	3.09	45.41	35.27
Current Unearned Revenue	103.36	97.42	85.65	96.56	93.64
Other Current Liabilities	405.36	379.29	373.87	482.86	555.88
Total Current Liabilities	1,011	1,423	1,205	1,446	1,534
Long-Term Debt	1,273	1,181	1,494	1,416	1,486
Long-Term Leases	0.31	-	-	-	-
Pension & Post-Retirement Benefits	22.27	15.09	35.55	35.98	50.89
Long-Term Deferred Tax Liabilities	88.52	88.98	88.45	38.15	38.28
Other Long-Term Liabilities	42.54	44	30.37	32.68	34.12
Total Liabilities	2,438	2,752	2,853	2,968	3,144
Common Stock	1,902	1,811	1,677	1,677	1,677
Additional Paid-In Capital	924.14	924.14	924.14	929.97	963.52
Retained Earnings	713.02	648.43	634.15	444.41	210.68
Comprehensive Income & Other	-95.25	-120.76	-137.17	-121.37	-129.18
Total Common Equity	3,444	3,263	3,098	2,930	2,722
Minority Interest	271.3	282.98	299.54	286.62	354.94
Shareholders' Equity	3,715	3,546	3,398	3,217	3,077
Total Liabilities & Equity	6,153	6,298	6,251	6,185	6,221
Total Debt	1,510	1,902	1,945	1,913	2,134
Net Cash (Debt)	-515.14	-724.46	-863.71	-668.74	-889.35
Net Cash Per Share	-2.70	-3.80	-4.53	-3.51	-4.68
Filing Date Shares Outstanding	190.2	190.2	190.2	190.2	190.2
Total Common Shares Outstanding	190.2	190.2	190.2	190.2	190.2
Working Capital	1,518	1,202	1,444	1,333	1,169
Book Value Per Share	18.11	17.16	16.29	15.41	14.31
Tangible Book Value	3,384	3,191	3,027	2,843	2,605
Tangible Book Value Per Share	17.79	16.78	15.91	14.95	13.70
Land	717.58	717.58	717.58	717.58	717.58
Buildings	3,224	3,195	2,978	2,927	2,882
Machinery	2,461	2,350	2,195	2,027	1,960
Construction In Progress	51.72	31.59	129.71	72.62	66.32

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.